Thymos Health
Your Guillain-Barré Syndrome Journey

One week you were fine.
Then you couldn't walk, or breathe on your own.
Recovery is still not guaranteed.

You're not alone. This is how Guillain-Barré syndrome (GBS) is typically managed in the hospital — and an honest look at what that admission costs, and what recovery actually looks like, over time.

1–2 per 100K people develop Guillain-Barré syndrome each year — the most common cause of acute flaccid paralysis in the U.S.1
22% of hospitalized patients require mechanical ventilation.2
2.8–4.4% is the in-hospital mortality rate, higher still in ICU-level cases.2
$116–158K is the average hospitalization cost, depending on treatment chosen.3

How Guillain-Barré syndrome is typically treated

Unlike most other autoimmune conditions, Guillain-Barré syndrome is usually a single acute event rather than a lifelong chronic disease — but the treatment choice made in the first days of admission has lasting consequences for both recovery and cost.

Mark where you are in your journey and we'll show you the full picture.

Step 1: On admission, your team starts Diagnosis, Monitoring & Supportive Care
Nerve conduction studies, spinal fluid analysis, and close monitoring of breathing and swallowing function
What your doctor says
"Your weakness pattern and reflex loss are consistent with Guillain-Barré syndrome. We need to monitor your breathing very closely — this can worsen quickly over the first 1–2 weeks."
Early recognition is critical to preventing respiratory crisis
Up to 22% of patients progress to needing a ventilator2
Autonomic instability (heart rate, blood pressure) is common and serious
Typical initial workup cost before insurance ~$8,000–$20,000
Providers seen before this was prescribed
How long was your initial hospital stay?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this treatment
$0
Disease-modifying treatment started — usually within days of diagnosis
Step 2: Your team starts disease-modifying treatment with IVIG or Plasma Exchange (PLEX)
IVIG 0.4g/kg/day × 5 days, or 5 sessions of therapeutic plasma exchange — equally recommended first-line options
What your doctor says
"We have two equally effective first-line treatments: IVIG or plasma exchange. IVIG is more common in U.S. practice because it's more convenient to administer, even though it's the more expensive of the two."
IVIG and PLEX are considered equally efficacious4
IVIG direct drug cost is more than 2× that of PLEX5
IVIG patients: shorter ventilator time and fewer infections in one large study6
Typical direct treatment cost before insurance ~$10,000–$16,000
How long did your treatment course last?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this treatment
$0
Inadequate improvement in the first 2 weeks — escalation considered
Step 3: For inadequate early improvement, your team considers A Second Treatment Course or PLEX-After-IVIG
Repeat Step 1 and Step 2 for non-responders, despite lack of scientific evidence that its effective7
What your doctor says
"You haven't improved as much as we'd hoped in the first two weeks. We can consider a second round of treatment, although the evidence for this is less clear than for the first course."
Combination treatment increases cost and length of hospitalization without proven benefit7
Typical added cost before insurance ~$10,000–$20,000
How long did this additional course last?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this treatment
$0
When the acute illness becomes a long recovery — or something more: Long-term Disability
Weeks to months of inpatient rehabilitation, with a meaningful share of patients never fully returning to baseline — and a small subset transitioning to a chronic relapsing form
What Your Doctor says
"You've come a long way since your admission. Some residual weakness and fatigue may persist for months, or longer, even with the best treatment we have."
2.8% → 3.9%
In-hospital mortality at 6 vs. 12 months post-diagnosis2
22%
Require mechanical ventilation during the acute phase2
7% ICU / <2% ward
Mortality contrast between ICU-level and floor-level admissions2
$116–158K
Average acute hospitalization cost, by treatment chosen3
Acute-phase severity markers
Require mechanical ventilation Up to 22%
In-hospital mortality, overall 2.8–4.4%
Mortality in ICU-admitted patients >7%
Mortality in non-ICU-admitted patients <2%
What the recovery period and cost actually involve
🏥 The choice of first-line treatment measurably affects both recovery and the bill. In one statewide database analysis, IVIG patients had a shorter median hospital stay (7 vs. 14 days), fewer in-hospital infections, and lower average hospitalization costs than plasmapheresis patients ($115,950 vs. $158,000).3
🌀 Adding a second treatment doesn't clearly help. A critical reassessment found no association between adding plasma exchange after IVIG and improved short-term outcomes — only an association with increased cost and longer hospitalization.7
🧠 Autonomic instability is a serious, under-discussed complication. Cardiac arrhythmias and blood pressure instability are common during the acute phase and are a major contributor to ICU-level mortality risk, independent of respiratory failure.
🔁 A small subset of patients don't have a truly monophasic course. Some patients initially diagnosed with Guillain-Barré syndrome go on to develop a relapsing or chronic course consistent with CIDP — a distinction that matters enormously for long-term treatment planning and is sometimes only clear in retrospect.
⚠ “Acute” does not mean “short” for every patient
Most Guillain-Barré syndrome patients do recover, and treatment is genuinely effective when started early. But a meaningful minority face a recovery measured in months to years, some degree of permanent residual weakness, and — rarely — an ongoing chronic course that the initial “acute illness” framing doesn't prepare anyone for.

What Guillain-Barré syndrome is really costing you

The hospitalization bill is only the beginning. Inpatient rehabilitation, outpatient physical therapy, and lost income during a recovery that can stretch for months all add up long after discharge.

Based on your journey above–adjust the numbers to match your situation.
Work days missed for treatment and recovery in the last 12 months
Your hourly wage (for lost income calculation)
Your estimated total cost of your Guillain-Barré syndrome episode and recovery $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Residual weakness and fatigue during recovery commonly reduce work capacity well beyond the days formally missed
If your care reaches the last phase of this journey — A Second Treatment Course or PLEX-After-IVIG
$0
Projected patient out-of-pocket for a full year at that phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet).

What your insurer is paying

Guillain-Barré syndrome generates most of its cost in a single, intense hospitalization — but the treatment choice made in the first 48 hours drives a real difference in what that admission ultimately costs.

Acute Hospitalization Perspective — Commercial Insurance
What your health plan spends on your Guillain-Barré syndrome admission
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated total payer cost for your Guillain-Barré syndrome episode $0
IVIG / PLEX treatment cost (payer portion)
~80% of direct treatment cost after patient coinsurance; IVIG drug costs alone can exceed 2× those of plasma exchange
$0
Hospitalization costs (ICU, ventilator, nursing, rehab)
The dominant cost driver — average total hospitalization cost runs $116,000–$158,000 depending on treatment and severity
~$130,000
Did your care include ICU admission or mechanical ventilation?
Roughly 1 in 5 hospitalized Guillain-Barré syndrome patients require mechanical ventilation, which is one of the largest single cost multipliers in this admission
Average hospitalization costs ran $115,950 for IVIG vs. $158,000 for plasmapheresis in one 5-year statewide analysis — a real cost difference between two “equally effective” first-line options.
Payer cost projection if care reaches the last phase of this journey — A Second Treatment Course or PLEX-After-IVIG
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ Why the first-line choice matters more than it seems
IVIG and plasma exchange are considered equally efficacious, but real-world data show meaningfully different costs and hospital courses between them — and no added benefit at all from combining both. The treatment decision made in the first 48 hours may be the single biggest cost lever in this entire episode.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented range of what happens across the severity spectrum of Guillain-Barré syndrome, even with prompt treatment.

Based on peer-reviewed clinical data
Documented range of outcomes for hospitalized Guillain-Barré syndrome patients
🫁
22% of hospitalized patients require mechanical ventilation during the acute phase of illness2
⚠️
2.8–4.4% in-hospital mortality rate overall, rising above 7% specifically among ICU-admitted patients2
💊
Equally effective — IVIG and plasma exchange are considered equivalent first-line options; the choice mainly affects cost and convenience, not outcome4
💰
$116–158K average total hospitalization cost range, depending on which first-line treatment is chosen3
✦ A different journey exists

Thymos Health offers another way

Conventional Guillain-Barré syndrome care is excellent at acute crisis management, but coordination often ends once you leave the hospital — even though recovery can take months to years. Thymos goes further – synthesizing your acute course, nerve studies, and rehabilitation progress to build a coordinated long-term recovery plan, and to watch for the rare cases that evolve into a chronic course.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 6 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Services Research, 2011. Guillain-Barré syndrome is the most common cause of acute neuromuscular paralysis in the U.S., with an annual incidence of 1–2 per 100,000.
PMC: PMC3121582
[2] Comparing Guillain-Barré syndrome outcomes between rural and urban hospitals in the United States: A retrospective cohort study. PMC, 2025 (n>10,000 Guillain-Barré syndrome hospitalizations). Up to 22% of patients require mechanical ventilation; in-hospital mortality 2.8–4.4% overall, exceeding 7% in ICU-admitted patients vs. under 2% for non-ICU patients; mortality 2.8% at 6 months rising to 3.9% at 12 months.
PMC: PMC12463200
[3] IVIg Versus Plasmapheresis Outcomes and Costs in Patients Diagnosed with Guillain-Barré Syndrome (2009-2013): A New York SPARCS Database Report. Neurology, 2016. Average hospitalization cost: $115,950 (IVIG) vs. $158,000 (plasmapheresis); IVIG group had shorter median length of stay (7 vs. 14 days) and fewer in-hospital infections (19% vs. 26%).
Source: neurology.org
[4] Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Services Research, 2011, citing the 1997 Plasma Exchange/Sandoglobulin GBS Trial: IVIg and plasma exchange are considered to have equal therapeutic benefit.
PMC: PMC3121582
[5] Same cost-minimization analysis (PMC3121582): direct cost of a 5-day IVIg course (2.0 g/kg) was $10,329.85, more than double the $4,638.16 direct cost of a 5-session TPE (plasma exchange) course.
PMC: PMC3121582
[6] Same SPARCS database report (Neurology, 2016): IVIG patients required less mechanical ventilation (2% for <96 hrs, 8% for >96 hrs) than plasmapheresis patients (5% and 18% respectively).
Source: neurology.org
[7] Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: Critical reassessment of effectiveness and cost-efficiency. PubMed, retrospective chart review of 46 patients (1995–2005). No association found between adding plasma exchange after IVIG and improved short-term outcomes; combination therapy was associated with increased cost and duration of hospitalization.
PMID: 21386771